Mounjaro is administered through a once-weekly injection, similar to most GLP-1 receptor agonists, but its dual mechanism offers a potentially more comprehensive approach to managing diabetes symptoms and body weight
Industry developments include AbbVies USD2.23 billion deal with Gubra A/S to develop an amylin-targeting obesity drug, and Eli Lillys strategic price reduction for its weight-loss drug Zepbound to maintain market share
References: Taylor EN, Stampfer MJ, Curhan GC
New oral options and changing manufacturer programs are shifting prices and access
As advocates for the millions of people we serve, we drive lower medication costs through negotiations with the pharmaceutical manufacturers, and were making it easier than ever for health plan sponsors to cover GLP-1s for weight loss, Harold Carter, senior vice president of trade relations at Evernorth Health Services pharmacy benefit manager division Express Scripts, said in the news release
